Literature DB >> 9339823

Botulinum toxin: from poison to remedy.

K R Kessler1, R Benecke.   

Abstract

Botulinum toxins, exotoxins of Clostridium botulinum, are the most toxic naturally occurring substances known to man. For more than a century they are known to be the cause of botulism, a nowadays rare intoxication with spoiled food that leads to generalized flaccid weakness of striated muscle including pharyngeal and respiratory musculature. The toxins act primarily at peripheral cholinergic motor nerve endings by blocking the release of the neurotransmitter acetylcholine. As a consequence, action potentials in the motor nerve can no longer be transmitted to the muscle. This lack in transmission, clinically appearing as weakness, may disable or actually critically endanger affected patients. However, in certain neurological diseases characterized by an abnormal increase in muscle tone or activity, for example dystonia or spasticity, a reduction in signal transmission may actually be beneficial. Around 1980 local injections of minute amounts (in the order of 0.5 ng) of Botulinum toxin type A were first successfully used in a neurological disorder named blepharospasm which is characterized by an involuntary squinting of the eyes. Since then Botulinum toxin has developed rapidly from a frightful poison to a safe therapeutic agent with a remarkable beneficial impact on the quality of life of many thousands of patients worldwide. This review tries to outline in brief the characteristics of Botulinum toxins, their mechanism of action and the various indications for clinical use as a therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9339823

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  10 in total

Review 1.  Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Authors:  Wolfgang H Jost; Jörg Blümel; Susanne Grafe
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Black tea extract, thearubigin fraction, counteract the effects of botulinum neurotoxins in mice.

Authors:  E Satoh; T Ishii; Y Shimizu; S Sawamura ; M Nishimura
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 3.  Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.

Authors:  David P Figgitt; Stuart Noble
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Effects of botulinum toxin type A on vibration induced facilitation of motor evoked potentials in spasmodic torticollis.

Authors:  P P Urban; R Rolke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

5.  Small molecules showing significant protection of mice against botulinum neurotoxin serotype A.

Authors:  Yuan-Ping Pang; Jon Davis; Shaohua Wang; Jewn Giew Park; Madhusoodana P Nambiar; James J Schmidt; Charles B Millard
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

6.  Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F.

Authors:  James J Schmidt; Robert G Stafford
Journal:  Appl Environ Microbiol       Date:  2003-01       Impact factor: 4.792

Review 7.  Bacterial toxins: friends or foes?

Authors:  C K Schmitt; K C Meysick; A D O'Brien
Journal:  Emerg Infect Dis       Date:  1999 Mar-Apr       Impact factor: 6.883

8.  Assessing adverse effects of intra-articular botulinum toxin A in healthy Beagle dogs: A placebo-controlled, blinded, randomized trial.

Authors:  Helka M Heikkilä; Tarja S Jokinen; Pernilla Syrjä; Jouni Junnila; Anna Hielm-Björkman; Outi Laitinen-Vapaavuori
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

9.  Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design.

Authors:  Yuan-Ping Pang; Anuradha Vummenthala; Rajesh K Mishra; Jewn Giew Park; Shaohua Wang; Jon Davis; Charles B Millard; James J Schmidt
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

10.  Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A.

Authors:  Jing Tang; Jewn Giew Park; Charles B Millard; James J Schmidt; Yuan-Ping Pang
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.